A Case of Anti-Synthetase Syndrome Successfully Treated with Mycophenolate Mofetil and Rituximab but No Corticosteroids
Agnieszka Ewa Sieradzka, Bruno Naccini, Massimiliano Fontana
European Journal of Case Reports in Internal Medicine · 2022
doi:10.12890/2022_003324 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
A patient with antisynthetase syndrome with pulmonary and muscular involvement was treated with immunosuppressive agents without corticosteroids. Rituximab was added to mycophenolate mofetil therapy with improvement in lung functional and imaging findings and normalization of creatine kinase levels.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.